Orthocell’s record revenue for FY24 has been reported in Business News.
Proactive Interview | Record-breaking revenue for FY24
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to discuss the Company’s record-breaking revenue for the June 24 quarter and for FY24.
Orthocell Continues Impressive Growth with Record Quarterly and Yearly Revenue Achieved
Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million – up 30.40% from the previous financial year, FY23.
Petra Capital Research Report | June 2024
Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share.
Orthocell applies for TGA market approval for SmrtGraftâ„¢
Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraftâ„¢ tendon repair device, in preparation for its introduction into the Australian tendon repair and regeneration market.
Remplirâ„¢ nerve repair study published in peer-reviewed clinical journal
Orthocell has announced that results from the Remplirâ„¢ nerve regeneration clinical trial have been published in a high profile clinical journal.
Orthocell receives $3.05m R&D tax incentive refund
Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial year 2022/2023.
Quarterly Report – Period To 31 March 2024
Orthocell has today published its Quarterly Report for the period ended 31 March 2024.
Proactive Interview with Paul Anderson
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to provide an update on the Company’s market authorisation study for nerve repair device, Remplirâ„¢.
Orthocell Successfully Completes Surgeries for Remplirâ„¢ US Market Authorisation
Orthocell has announced that it has successfully completed the first stage of the Remplirâ„¢ US 510(k) market authorisation nerve repair study.